Real-time Estimate Cboe BZX 01:15:54 2024-04-29 pm EDT 5-day change 1st Jan Change
0.588 USD -11.61% Intraday chart for Biomerica, Inc. -18.06% -52.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biomerica Enters Distribution Deal to Provide Home Screening Tests in UAE MT
Biomerica Provides Update on inFoods IBS Expansion CI
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 CI
Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board CI
Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors CI
Biomerica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023 CI
Top Premarket Decliners MT
Biomerica Shares Rise After FDA 510(k) Clearance for H Pylori Bacteria Test DJ
Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria CI
Biomerica, Inc. Expands in Foods IBS Reach with Addition of Several New GI Groups CI
Biomerica, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2023 CI
Biomerica Says Dubai Approves Insurance Reimbursement for Colorectal Disease Screening Test MT
Jack Kenny Joins Biomerica?S Board of Directors CI
Biomerica, Inc. Reports Earnings Results for the Full Year Ended May 31, 2023 CI
Biomerica's Colorectal Disease Screening Test to be Available in CVS Stores in September MT
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Index CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Index CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell 3000E Growth Index CI
Biomerica, Inc.(NasdaqCM:BMRA) dropped from Russell Microcap Growth Index CI
Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients CI
Certain Stock Options of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023. CI
Certain Common Stock of Biomerica, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2023. CI
Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome CI
Biomerica, Inc. Announces inFoods IBS Test Now Available at Gastro Health CI
Biomerica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023 CI
Chart Biomerica, Inc.
More charts
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Company’s two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BMRA Stock
  4. News Biomerica, Inc.
  5. Biomerica's Colorectal Disease Screening Test to be Available in CVS Stores in September